Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

10/22/2026, 1:00 PM • GlobeNewswire

Vanguard Health Care ETF vs iShares U.S. Healthcare ETF

Vanguard Health Care ETF (VHT) and iShares U.S. Healthcare ETF (IYH) both provide U.S. healthcare sector exposure with identical 5-year returns, but VHT offers significantly better value with 411 holdings, a lower 0.09% expense ratio versus IYH's 0.37%, and a higher 1.4% dividend yield. While IYH takes a more concentrated approach with 100 stocks focused on large-cap healthcare companies, VHT is recommended for most investors seeking lower costs and broader diversification.

10/21/2026, 6:30 PM • The Motley Fool

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR. North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

10/21/2026, 1:00 PM • GlobeNewswire

Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.

With the Federal Reserve likely to maintain or raise interest rates through the end of 2026, dividend stocks like AbbVie are positioned to perform well. AbbVie, a pharmaceutical company with over 50 years of dividend increases, offers resilience in a high-rate environment due to its strong balance sheet, fixed-rate debt, and non-rate-sensitive business model.

10/20/2026, 11:45 AM • The Motley Fool

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.

10/19/2026, 1:00 PM • GlobeNewswire

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It

Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments.

10/19/2026, 4:10 AM • The Motley Fool

Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.

Ken Griffin's Citadel significantly increased positions in healthcare stocks during Q2, boosting AbbVie by 546%, Abbott Laboratories by 349%, and Eli Lilly by 291%. The moves suggest Griffin is seeking defensive, dividend-yielding stocks amid anticipated market volatility. AbbVie, a Dividend King with 54 consecutive years of dividend increases, is highlighted as a strong buy with attractive valuation and solid earnings growth.

10/18/2026, 8:15 AM • The Motley Fool

Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle

AbbVie is positioned as a reliable dividend stock that avoids high-yield trap characteristics. With 54 consecutive years of dividend increases, strong free cash flow generation, fixed-rate debt, and blockbuster drugs Skyrizi and Rinvoq generating over $7.5 billion quarterly, AbbVie maintains Dividend King status regardless of interest rate cycles. The company's robust pipeline of 90 clinical programs provides future revenue stability.

10/17/2026, 4:44 AM • The Motley Fool

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

AbbVie, a Dividend King with 53 consecutive years of dividend increases, would require 723 shares (approximately $206,358) to generate $5,000 in annual dividends at its current price. Despite a modest 2.4% forward yield, the pharmaceutical giant's strong portfolio of blockbuster drugs, low P/E ratio of 16, and 93% stock rally over three years make it an attractive long-term income investment, even compared to higher-yielding alternatives like Pfizer.

10/16/2026, 5:28 PM • The Motley Fool

The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF

iShares Core High Dividend ETF (HDV) and Fidelity High Dividend ETF (FDVV) offer contrasting approaches to dividend investing. HDV emphasizes defensive sectors like energy and staples with lower volatility and a 0.08% expense ratio, while FDVV incorporates tech exposure with higher growth potential but greater volatility and a 0.15% expense ratio. HDV has delivered 12.8% CAGR since 2021 with a 2.9% yield, while FDVV achieved 13.5% CAGR with a 2.8% yield. The choice depends on whether investors prioritize conservative income or growth-oriented dividend strategies.

10/15/2026, 1:31 PM • The Motley Fool

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight

Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.

10/15/2026, 1:00 PM • GlobeNewswire

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

10/15/2026, 10:16 AM • The Motley Fool

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?

The article compares two healthcare ETFs: IBB (biotech-focused) and IYH (broad healthcare). IBB has delivered stronger 1-year returns (38% vs 17.4%) but exhibits higher volatility and deeper drawdowns. IYH offers lower costs, higher dividend yield, and broader diversification, making it better for most long-term investors, while IBB suits those with conviction in biotech momentum who can tolerate volatility.

10/11/2026, 7:09 PM • The Motley Fool

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

10/10/2026, 10:15 PM • The Motley Fool

A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens

Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments.

10/09/2026, 10:30 AM • The Motley Fool